Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

被引：0
|
作者：
Zatreanu, Diana A.
Robinson, Helen M. R.
Alkhatib, Omar
Boursier, Marie
Finch, Harry
Geo, Lerin
Grande, Diego
Grinkevich, Vera
Heald, Robert
Langdon, Sophie
Majithiya, Jayesh
McWhirter, Claire
Martin, Niall M. B.
Moore, Shaun
Neves, Joana
Rajendra, Eeson
Ranzani, Marco
Schaedler, Theresia
Stockley, Martin
Wiggins, Kimberley
Brough, Rachel
Sridhar, Sandhya
Gulati, Aditi
Shao, Nan
Badder, Luned M.
Novo, Daniela
Knight, Eleanor G.
Marlow, Rebecca
Haider, Syed
Callen, Elsa
Hewitt, Graeme
Schimmel, Joost
Prevo, Remko
Alli, Christina
Ferdinand, Amanda
Bell, Cameron
Blencowe, Peter
Calder, Mathew
Charles, Mark
Curry, Jayne
Ekwuru, Tennyson
Ewings, Katherine
Nussenzweig, Andre
Tijsterman, Marcel
Tutt, Andrew
Boulton, Simon J.
Higgins, Geoff S.
Pettitt, Steve
Smith, Graeme C. M.
Lord, Christopher J.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P056
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Leveraging synthetic lethality to target convergent therapeutic resistance
    Wood, Kris C.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
  • [32] Leveraging Synthetic Lethality to Target Convergent Therapeutic Resistance
    Wood, Kris C.
    FASEB JOURNAL, 2017, 31
  • [33] Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer
    Marise R. Heerma van Voss
    Justin D. Brilliant
    Farhad Vesuna
    Guus M. Bol
    Elsken van der Wall
    Paul J. van Diest
    Venu Raman
    Medical Oncology, 2017, 34
  • [34] Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
    Chakraborty, Goutam
    Patail, Nabeela Khan
    Hirani, Rahim
    Nandakumar, Subhiksha
    Mazzu, Ying Z.
    Yoshikawa, Yuki
    Atiq, Mohammad
    Jehane, Lina E.
    Stopsack, Konrad H.
    Lee, Gwo-Shu Mary
    Abida, Wassim
    Morris, Michael J.
    Mucci, Lorelei A.
    Danila, Daniel
    Kantoff, Philip W.
    CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1792 - 1806
  • [35] Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer
    van Voss, Marise R. Heerma
    Brilliant, Justin D.
    Vesuna, Farhad
    Bol, Guus M.
    van der Wall, Elsken
    van Diest, Paul J.
    Raman, Venu
    MEDICAL ONCOLOGY, 2017, 34 (03)
  • [36] Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
    Lord, Christopher J.
    Tutt, Andrew N. J.
    Ashworth, Alan
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 455 - 470
  • [37] Increasing the Synthetic Lethality of PARP Inhibition in Glioblastoma Cells by Depletion of Nuclear BRCA1
    Sizemore, S.
    Mohammad, R.
    Schnedl, B.
    Chakravarti, A.
    Xia, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S780 - S780
  • [38] BYPASSING GLIOBLASTOMA RESISTANCE TO EGFR INHIBITORS BY SYNTHETIC LETHALITY
    Chen, Clark
    Shen, Ying
    Nitta, Masayuki
    Futalan, Diahnn
    Taich, Zack
    Treiber, Jeffrey
    Stevens, Deanna
    Chen, Hong-Zhuan
    Carter, Bob
    Esashi, Fumiko
    Sarkaria, Jann
    Furnari, Frank
    Cavenee, Webster
    Desai, Arshad
    NEURO-ONCOLOGY, 2014, 16
  • [39] Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells
    Barszczewska-Pietraszek, Gabriela
    Czarny, Piotr
    Drzewiecka, Malgorzata
    Blaszczyk, Maciej
    Radek, Maciej
    Synowiec, Ewelina
    Wigner-Jeziorska, Paulina
    Sitarek, Przemyslaw
    Szemraj, Janusz
    Skorski, Tomasz
    Sliwinski, Tomasz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [40] OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
    Baquero, Juan Miguel
    Marchena-Perea, Erik
    Mirabet, Rocio
    Torres-Ruiz, Raul
    Blanco-Aparicio, Carmen
    Rodriguez-Perales, Sandra
    Helleday, Thomas
    Benitez-Buelga, Carlos
    Benitez, Javier
    Osorio, Ana
    FRONTIERS IN ONCOLOGY, 2022, 12
12345